A cancer biotech attracts another deep-pocketed partner in Gilead

Following rivals like Bristol Myers Squibb and Merck, Gilead has linked up with Dragonfly Therapeutics to develop new immunotherapies based on "natural killer cell engagers."

Click to view original post